Alpha Tau Medical (NASDAQ:DRTS) Stock Price Down 9.4% – Should You Sell?

Alpha Tau Medical Ltd. (NASDAQ:DRTS) shares were down 9.4% during mid-day trading on Friday . The stock traded as low as $9.78 and last traded at $9.93. Approximately 276,319 shares changed hands during trading, a decline of 40% from the average daily volume of 462,684 shares. The stock had previously closed at $10.96.

Key Headlines Impacting Alpha Tau Medical

Here are the key news stories impacting Alpha Tau Medical this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating on Alpha Tau Medical and maintained a $15.00 price target, which is above the stock’s recent trading range and can bolster investor confidence. Alpha Tau Medical (NASDAQ:DRTS) Receives “Buy” Rating from HC Wainwright
• Neutral Sentiment: The firm also published updated earnings estimates for 2026 and 2027, keeping forecasts in a similar loss-making range, which signals continued expectations for gradual progress rather than a major change in the business outlook.
• Negative Sentiment: HC Wainwright cut its EPS estimates for Q2 2026, Q3 2026, Q4 2026, and FY2026, reflecting somewhat softer short-term profitability expectations.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on DRTS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Alpha Tau Medical in a report on Wednesday. Citigroup boosted their price objective on Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. Finally, LADENBURG THALM/SH SH upped their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $11.50.

Alpha Tau Medical Stock Down 5.9%

The firm has a fifty day moving average price of $7.96 and a 200 day moving average price of $6.52. The company has a quick ratio of 7.45, a current ratio of 7.79 and a debt-to-equity ratio of 0.09. The company has a market cap of $907.74 million, a P/E ratio of -15.39 and a beta of 1.11.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Equities research analysts forecast that Alpha Tau Medical Ltd. will post -0.56 earnings per share for the current year.

Institutional Investors Weigh In On Alpha Tau Medical

A number of hedge funds have recently modified their holdings of DRTS. Apella Capital LLC acquired a new stake in shares of Alpha Tau Medical during the fourth quarter worth about $1,892,000. Daytona Street Capital LLC acquired a new stake in shares of Alpha Tau Medical during the fourth quarter worth about $749,000. Mariner LLC raised its position in shares of Alpha Tau Medical by 185.8% during the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock worth $556,000 after purchasing an additional 80,129 shares during the period. Millennium Management LLC raised its position in shares of Alpha Tau Medical by 185.7% during the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock worth $534,000 after purchasing an additional 70,081 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in shares of Alpha Tau Medical during the first quarter worth about $286,000. Institutional investors and hedge funds own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.